Amgen’s Amjevita (adalimumab-atto) has just launched on the US market, meaning it becomes the first biosimilar to reference the blockbuster drug Humira. The biosimilar drug is now commercially available to US patients, and is intended to treat numerous rheumatic conditions.
Available in a prefilled syringe or an auto-injector pen, the drug is the first of ten adalimumab biosimilars expected to launch this year.
